Table of Contents
Journal of Amino Acids
Volume 2017, Article ID 7021071, 6 pages
Review Article

Efficacy of Memantine in Schizophrenic Patients: A Systematic Review

1Department of Neuroscience Imaging and Clinical Science, “G. d’Annunzio” University of Chieti, Chieti, Italy
2Department of Mental Health, National Health Trust, Chieti, Italy

Correspondence should be addressed to Maria Chiara Spano; moc.liamg@onaps.araihc.m

Received 30 June 2016; Revised 27 September 2016; Accepted 27 December 2016; Published 24 January 2017

Academic Editor: Mario Herrera-Marschitz

Copyright © 2017 Giuseppe Di Iorio et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Several evidences support the hypothesis that glutamatergic dysfunction may be implicated in the pathogenesis of schizophrenia and in the last few years great interest has been focused on the role of the N-methyl-D-aspartate receptor (NMDAR). Glutamate is the main excitatory neurotransmitter in human CNS and it plays a prominent role in synaptic plasticity, learning, and memory and other cognitive functions. Increasing interest in memantine add-on therapy in schizophrenic patients with negative and cognitive symptoms may suggest that memantine could be a new promising treatment in schizophrenia. The aim of this update was to evaluate clinical data about the memantine effectiveness in schizophrenic patients. Our systematic review of the literature highlights that memantine therapy in schizophrenic patients seems to improve mainly negative symptoms while positive symptoms and cognitive symptoms did not improve significantly.